Physician profile

Thomas George Planzos

General Practice (Dentist) · Brooklyn, NY

NPI 1447355284

$1,665.23

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Gift$213.00
Food and Beverage$82.18

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Acteon INC $997.00 2019-2022
A-Dec, INC. $501.44 2019-2024
Dentsply Sirona INC $68.68 2020-2023 Palodent Plus Ez Coat Sectional Matrix System
Zimvie INC. $43.80 2023
Voco America INC. $22.01 2022
3m Company $16.56 2023 Scotchbond Universal Plus, 3m Espe Filtek Supreme Ultra Universal Restorative, 3m Relyx
Orapharma, A Division of Bausch Health US, LLC $15.74 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas George Planzos

$1,665.23

in general payments reported 2019-2025

Years
2019-2024
Top company
Acteon INC

https://glasscript.com/doctor/432953/thomas-george-planzos

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.